Searching for innovative biological drugs thumbnail
Pause
Mute
Subtitles not available
Playback speed
0.25
0.5
0.75
1
1.25
1.5
1.75
2
Full screen

Searching for innovative biological drugs

Published on Jun 28, 201973 Views

Noncommunicable diseases (NCDs), also known as chronic diseases, tend to be of long duration and are the result of a combination of genetic, physiological, environmental and behavioral factors. The ma

Related categories

Chapter list

Searching for innovative biological drugs00:00
The tremendous burden of cardiovascular disorders03:57
Time line showing the development of drugs against heart failure05:27
Biotherapeutics06:24
Biotherapeutics for myocardial ischemia and heart failure07:56
Cytokines and growth factors12:34
Can we select for cardioprotective factors in vivo?13:18
Gene transfer using Adeno-Associated Virus (AAV) vectors14:08
FunSel for the in vivo selection of factors protecting against myocardial infarction - 117:18
AAV arrayed, barcoded libraries18:54
FunSel for the in vivo selection of factors protecting against myocardial infarction - 220:25
AAV9-Ghrelin preserves myocardial function after infarction - 121:26
Ghrelin22:51
AAV9-Ghrelin preserves myocardial function after infarction - 223:32
Ghrelin is a power inducer of autophagy and mitophagy24:19
Cytokines that mediate cardiac engraftment of cells?26:24
FunSel for the selection of cytokines inducing cardiac retention of stem cells26:49
FunSel for the selection of cytokines sustaining BM-MSC engraftment28:24
BM-MSCs treated with Cardiotrophin-128:30
Cardiotrophin 1 induces expression of FAK in BM-MSCs29:09
1 h CTF 1 treatment30:06
CTF 1 h 5 ng30:08
FunSel for the in vivo selection of factors protecting pancreas β-cells30:10
The holy grail of cardiac regeneration31:27
The mammalian heart stops regenerating early after birth31:55
Cardiomyocytes stop proliferating after birth - 132:59
The Oxygen - Rich Postnatal Environment34:55
Cardiomyocytes stop proliferating after birth - 235:47
Regulatory T cells (T-regs) are expanded during pregnancy36:01
Non immunological functions of Tregs37:14
Paracrine effect37:52
Is really the adult heart a postmitotic organ?41:12
Regenerative potential of Ambystoma mexicanum (Axolotl)41:57
Several species other than mammals regenerate the heart42:58
Heart Regeneration in Zebrafish43:20
Transient Regenerative Potential44:32
Functional cardiac tissue created by neonatal cardiomyocytes45:20
New Hypotheses46:04
Carbon dating of cardiomyocytes in human hearts47:04
Screening for cardiomyocyte proliferation using a library of microRNA mimics50:19
40 human miRNAs increase both rat and mouse cardiomyocyte proliferation - 151:31
40 human miRNAs increase both rat and mouse cardiomyocyte proliferation - 252:57
miRNAs increasing myocardial proliferation in vivo – newborn rat heart - 153:27
miRNAs increasing myocardial proliferation in vivo – newborn rat heart - 253:33
miRNAs increasing CM proliferation in vivo53:51
miR-590 and miR-199a preserve myocardial function after MI54:05
miR-590 and miR-199a markedly reduce infarct size55:07
Mechanisms?55:28
Identification of miR-590-3p and miR-199a-3p target genes55:29
Among the 641 genes downregulated by miR-590-3 and miR-199a-3p there are55:56
Identification of miR-590-3p and miR-199a-3p target genes56:28
Identification of miR-590 and miR-199a target genes by deep sequencing56:40
miRNAs promoting cardiomyocyte proliferation activate YAP-induced transcription57:09
Letters57:30
Letter57:59
Effect in human cardiomyocytes?58:01
Effect of selected miRNAs on the proliferation of human ES cell-derived cardiomyocytes58:22
Human fetal cardiomyocyte proliferation - 158:56
Human fetal cardiomyocyte proliferation - 259:29
Human adult cardiomyocytes59:34
Human adult cardiomyocytes replicating DNA01:00:42
Effect in large animals?01:00:51
LAD Occlusion01:01:01
Reduce infarct size01:01:46
4 weeks after MI01:02:53
Infarct/fibrosis area - 101:04:11
Infarct/fibrosis area - 201:04:34
Infarct/fibrosis area - 301:05:04
Sudden cardiac death of AAV6- miR-199a-treated pigs01:05:18
Death of pig#66 at 8 weeks01:05:58
Small cell Hematoxylin Eosin clusters in hearts - 101:06:53
Small cell Hematoxylin Eosin clusters in hearts - 201:07:12
Small cell Hematoxylin Eosin clusters in hearts - 301:07:22
Small cell Hematoxylin Eosin clusters in hearts - 401:07:36
Small cell Hematoxylin Eosin clusters in hearts - 501:07:38
Cell Stem Cell01:08:07
Delivery?01:08:11
Prolonged effect of miRNA mimics after intra-cardiac injection01:08:42
miRNA mimics stimulate myocardial repair after MI01:09:23
Circulation Research01:09:47
Fibrotic diseases contribute to almost 50% of deaths worldwide01:10:08
Drug repurposing01:10:58
The use of genetically modified reporter animals01:11:46
SMA-RFP, COLL-EGFP mice01:12:31
High Throughput screening for FDA - 101:13:31
High Throughput screening for FDA - 201:13:34
Five top drugs inhibiting myofibroblast activation01:13:51
Haloperidol inhibit fibroblast migration and contraction force01:14:01
Fibroblasts do not express the Drd2 receptor01:14:20
Sigmar1 mediates the activity of Haloperidol in fibroblasts01:14:46
Haloperidol does not act on the canonical TGFb pathway01:14:49
Haloperidol increases intracellular calcium similar to known inducers of ER stress01:14:50
Haloperidol induces a mild ER stress01:14:53
Myofibroblast inhibition by Haloperidol requires the Notch pathway01:14:55
Haloperidol inhibits myofibroblast activation after myocardial infarction01:14:57
Haloperidol inhibits lung fibrosis01:15:12
Haloperidol inhibits cancer-associated fibroblasts (CAFs) and tumor growth01:15:28
Haloperidol inhibits myofibroblast activation01:15:29
Intereg - 101:16:05
Intereg - 201:16:12
Data Processing of Unknown Substances01:16:25
Dopamine effectively inhibits myofibroblast activation in vitro01:17:05
Dopamine effectively inhibits myofibroblast activation in vivo01:17:17
Collaborations01:17:23
Thanks01:17:32